Science Advance: Monoclonal antibody effective in treating life-threatening renal disease

A clinical study, completed at the ACTSI-supported Pediatric Research Center at Egleston, found that the monoclonal antibody eculizumab is effective in treating patients with atypical hemolytic uremic syndrome (aHUS), a life-threatening, chronic and progressive inflammatory disease. The results are published in a recent issue of the New England Journal of Medicine.


Share This Story